• Skipping Phase 1
  • Designing Phase 2 effectively as a Phase 3 registration trial

Pipeline

AssetIndicationPre-ClinicalIND-Enabling StudiesPhase 1Phase 2Phase 3
OK-101
Dry Eye
*Not requiredAnticipated start date Q4/2022

Uveitis

Allergic Conjunctivitis

OK-201
Discovery Program

OK-101 Anticipated IND Submission date Q3, 2022
* Ocular topical drug delivery
DrugIndicationStage
OK-101
Dry Eye IND-Enabling Studies*
Uveitis Pre-Clinical
Allergic Conjunctivitis Pre-Clinical
OK-201
Discovery Program
*OK-101 Anticipated IND Submission date Q3, 2022
Anticipated Phase 2 start date Q4, 2022